As of November 6, 2026, Actuate Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 6, 2026, naming 2 appointments. The latest filing names Martin H. Huber, appointed (Form 8-K, May 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Actuate Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Actuate Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-06. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Actuate Therapeutics, Inc. files it.
Also on the record for Actuate Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G, by Hexstone Capital LLC | 7.7% of the class | 5%+ stakes | Source |
| October 19, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 14, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 6, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| April 22, 2026 | Stake report, Schedule 13G/A, by Voss Capital, LP | 7.7% of the class | 5%+ stakes | Source |
| December 17, 2025 | Stake report, Schedule 13G, by Voss Capital, LP | 5.3% of the class | 5%+ stakes | Source |
| July 25, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| July 7, 2025 | Form D, private offering | $4.67M sold | Form D page | Source |
| April 10, 2025 | Form D, private offering | — | Form D page | Source |
| March 28, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| August 13, 2024 | IPO filing, Form 424B4 | $8 a share | IPO filings | Source |
| July 23, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
Selling to them or working with them? See who runs Actuate Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Actuate Therapeutics, Inc. and the records around it.
Actuate Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Form D filing Jul 2025
- Who owns it
Companies that share a holder
- Hexstone Capital LLC also filed stake reports on 6 other companies: Jet.AI Inc. (Nov 2026), Global Mofy AI Ltd (May 2026), Cellectar Biosciences, Inc. (Feb 2026)
- Voss Capital, LP also filed stake reports on 13 other companies: Five9, Inc. (Oct 2026), Cellebrite DI Ltd. (Aug 2026), ALTA EQUIPMENT GROUP INC. (Jul 2026)
Watch Actuate Therapeutics, Inc.
Get an email when Actuate Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Actuate Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Actuate Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Actuate Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-06 | In | 8-K, 2026-05-06 | |||
| 2026-05-06 | In | Director | 8-K, 2026-05-06 |
Who leads Actuate Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Martin H. Huber, appointed (filed 2026-05-06).
New leaders reset buying decisions — get the Full Report on Actuate Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Actuate Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Actuate Therapeutics, Inc.Every change, in the filing's words
Appointed: Martin H. Huber
On May 1, 2026, the Board of Directors ("Board") of Actuate Therapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board.
Appointed: Martin H. Huber, Director
Dr. Huber was appointed to fill a newly created Board seat resulting from the expansion of the Board from seven (7) to eight (8) directors, also effective upon his appointment.
- Dr. Huber will serve as a Class III director until the Company's 2027 annual meeting of stockholders, and until his successor is duly elected and qualified, or until his earlier resignation, death, or removal.
- Dr. Huber will serve on the Nominating and Corporate Governance Committee of the Board.
- Dr. Huber will receive compensation in accordance with the Company's non-employee Director Compensation Program, including an initial grant of non-statutory stock options to purchase 30,000 shares of common stock, vesting over a three year period, and an annual retainer, paid in equal quarterly installments, of $44,000.
- The Company also entered into the Company's standard form indemnification agreement with Dr. Huber.
- In connection with the appointment of Dr. Huber, the Company entered into a separate consulting agreement with Dr. Huber to provide additional research and development advisory services to the Company upon his appointment, with a quarterly consulting fee of $3,000.
- Dr. Huber was the President and Chief Executive Officer of Mersana Therapeutics, Inc ("Mersana") from 2023 to January 2026 (and a director from 2020 to January 2026) until Mersana was acquired by Day One Biopharmaceuticals.
- Prior to Mersana, he served as the President of R&D, and prior to that as Chief Medical Officer, of Xilio Therapeutics, Inc. from April 2020 to September 2023.
Tools for this story
Each opens in a new tab, filled in for Actuate Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.